Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Doctors and the DEA Free full text
Top Ten Searches
rosacea eczema alopecia ceramide keratosis pityriasis basal cell melanoma keratosis purpuraYour Article Summary
See Latest ArticlesNon-toxic melanoma therapy by a novel tubulin-binding agent
International Journal of Cancer, 09/23/09
Aneja R et al. – Unlike currently available chemotherapeutics, EM011 is non–toxic to normal tissues and most importantly, does not cause any immunosuppression and neurotoxicity. The data thus warrant a clinical evaluation of EM011 for melanoma therapy.
Related Articles
Predicting response to IL-2 therapy for metastatic melanoma
Expert Review of Anticancer Therapy, 11/12/09
Relevance Score: 67%
Single-institution Outcome of High-dose Interleukin-2 (HD IL-2) Therapy for Metastatic Melanoma and Analysis of Favorable Response in Brain Metastases
Anticancer Research, 11/11/09
Relevance Score: 67%
A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma
Cancer, 11/09/09
Relevance Score: 67%
Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy
The Oncologist, 10/30/09
Relevance Score: 67%
Pegylated interferons: Prospects for the use in the adjuvant and palliative therapy of metastatic melanoma
European Journal of Cancer, 10/29/09
Relevance Score: 66%
Today in Dermatologic Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Evaluation of EMMPRIN and MMP-2 in the prognosis of primary cutaneous malignant melanoma
Medical Oncology, 12/04/09
Cutaneous lymphangioma circumscriptum: frog spawn on the skin
International Journal of Dermatology, 12/03/09
Melanoma incidence and exposure to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers
Cancer Epidemiology, 12/03/09
Sponsor
Article Search
Sponsor